DA Davidson Maintains Buy on Axcelis Technologies, Raises Price Target to $145

DA Davidson analyst Hans Chung maintains Axcelis Technologies (NASDAQ:ACLS) with a Buy and raises the price target from $105 to $145.

byBenzinga Newsdesk

February 10, 2023

1 minute read

DA Davidson analyst Hans Chung maintains Axcelis Technologies (NASDAQ:ACLS) with a Buy and raises the price target from $105 to $145.

Citigroup Maintains Neutral on Hologic, Lowers Price Target to $75

By Benzinga Newsdesk

Today, 7:57 PM

Citigroup analyst Patrick Donnelly maintains Hologic (NASDAQ:HOLX) with a Neutral and lowers the price target from $78 to $75.

HOLX

Piper Sandler Maintains Neutral on Ceridian HCM Holding, Lowers Price Target to $85

By Benzinga Newsdesk

Today, 7:57 PM

Piper Sandler analyst Arvind Ramnani maintains Ceridian HCM Holding (NYSE:CDAY) with a Neutral and lowers the price target from $105 to $85.

CDAY

Pfizer, BioNTech Offers Update On Rolling Submission For Emergency Use Authorization Of COVID-19 Vaccine In Children 6 Months To 4 Years

By Benzinga Newsdesk

Today, 7:57 PM

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) today announced plans to extend their rolling submission to the U.S. Food and Drug Administration (FDA) seeking to amend the Emergency Use Authorization of the

BNTX

Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial

By Vandana Singh

Today, 7:57 PM

Iovance Biotherapeutics Inc (NASDAQ:IOVA) has announced additional data for LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) enrolled in…

IOVA

DA Davidson Maintains Buy on Axcelis Technologies, Raises Price Target to $145

Related Posts

Citigroup Maintains Neutral on Hologic, Lowers Price Target to $75

Piper Sandler Maintains Neutral on Ceridian HCM Holding, Lowers Price Target to $85

Pfizer, BioNTech Offers Update On Rolling Submission For Emergency Use Authorization Of COVID-19 Vaccine In Children 6 Months To 4 Years

Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial